other material
confidence high
sentiment neutral
materiality 0.85
Biofrontera to acquire US Ameluz/RhodoLED rights; royalty 12-15%, 10% equity stake
Biofrontera Inc.
- Upfront EUR 2,593,750 payment due June 30, 2025; condition to raise $8.5M preferred equity by same date.
- Royalty on US net sales: 12% up to $65M revenue, 15% above; minimum 80,000 tubes/year penalty clause.
- Sellers receive preferred stock convertible to 10% of fully diluted Biofrontera Inc. common equity.
- Sellers get 1-2 board seats as long as they hold preferred stock; term sheet void if conditions unmet.
- Buyer assumes all US supply costs and legal defense; stockholder vote required for conversion rights.